Cullen/Frost Bankers enters its Q1 2026 earnings call on April 30 with shorts unwinding sharply, options leaning bullish, and the Street split between cautious neutrals and a persistent Underweight from Morgan Stanley.
The most striking move in the data this week is the retreat in short positioning. Short interest dropped 13.4% over the past week to 3.3% of the free float — the fastest weekly unwind since March. The pullback follows a broader build that ran from late March through mid-April, when shares outstanding on loan peaked near 2.55 million before reversing. That reversal accelerated sharply on April 23, when short positions fell by roughly 300,000 shares in a single session. Borrowing remains exceptionally cheap at 0.47% annualised, up modestly on the week but still near multi-month lows. Availability in the lending pool is ample — the lending market shows no signs of stress, and the ORTEX short score has drifted lower all week, from 41.2 to 38.4, moving away from elevated territory and into firmly neutral ground.
Options positioning reinforces the constructive tone. The put/call ratio is running at just 0.07 — well below its 20-day average of 0.15 and near the bottom of its 52-week range of 0.05 to 1.56. In plain terms, call demand dominates the options market ahead of the print. The PCR has been declining steadily since mid-April, when it was sitting just above 0.15. That's a significant rotation toward upside exposure in the weeks immediately before a result.
The analyst picture is less uniformly bullish. Barclays raised its target to $155 on April 7, maintaining an Equal-Weight rating, while Evercore trimmed its target to $150 from $155 a day earlier, also holding neutral. Morgan Stanley is the outlier: its Underweight with a $133 target — below the current price of $142.80 — reflects ongoing concern about net interest margin compression and the bank's sensitivity to an inverted yield curve. The consensus mean target is $146.67, implying only modest upside from current levels. On valuation, the stock trades at a P/E of 13.7x and a P/B of 1.85x, both ticking higher over the past month as the share price recovered 6.8%. The dividend score ranks in the 97th percentile, a notable strength for income-oriented holders. Longer-term earnings momentum is solid — 90-day EPS momentum ranks in the 70th percentile — though the 30-day reading has softened to the 39th percentile, suggesting some near-term estimate drift.
Institutionally, the ownership base is stable and concentrated. BlackRock built a sizeable position in Q1, adding roughly 848,000 shares to reach 11.2% of outstanding. Vanguard holds 10.2% and added only marginally. Dimensional Fund Advisors increased its stake by around 107,000 shares through March 31. The base is dominated by passive and long-only managers, with no clear activist presence, which limits the risk of forced selling but also caps the upside surprise from institutional demand. Insider activity from February shows the CEO and several executives sold modest lots on February 5 alongside routine award grants — all at prices close to today's level, suggesting no particular urgency on the insider side.
The Q1 earnings history adds one data point: the last print in January produced a 1-day gain of nearly 2% and a 5-day move of 6.2%. With peers like CBSH and UMBF both up roughly 1.2% on the week while CFR edged only fractionally lower, the regional bank group broadly held its ground heading into the result. What the market gets on April 30 — particularly any guidance on deposit growth in the Texas market and the trajectory of net interest income without a Fed rate cut — will determine whether the options-driven call skew was well-placed or premature.
See the live data behind this article on ORTEX.
Open CFR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
